Inoue Kenji, Shiokawa Minako, Fujimoto Takayuki, Tomita Goji
Inouye Eye Hospital, Tokyo, Japan.
2nd Department of Ophthalmology, Toho University School of Medicine, Tokyo, Japan.
Clin Ophthalmol. 2014 Jun 19;8:1179-83. doi: 10.2147/OPTH.S60538. eCollection 2014.
To evaluate the effects of bimatoprost 0.03% single treatment for 3 years on intraocular pressure (IOP) and visual field performance.
We monitored the IOP of 62 patients with normal-tension glaucoma every 1-3 months. The Humphrey visual field test was performed every 6 months after treatment and the results obtained were compared to those before treatment. In addition, visual field performance was evaluated using trend and event analysis.
The mean ± standard deviation (SD) of IOP after treatment with bimatoprost for 3 years (13.6±3.1 mmHg) was significantly lower than that before treatment (16.8±2.4 mmHg, P<0.0001). No change was observed in the mean deviation and pattern SD values of the Humphrey visual field before and 3 years after treatment. Worsening of visual field performance was observed in one patient (3.0%) by using trend analysis and in four patients (12.1%) by using event analysis. Treatment was discontinued in 17 patients (27.4%) because of adverse reactions.
Bimatoprost 0.03% single treatment was effective in reducing the IOP at least during the 3 years of treatment, but visual field performance worsened by 3.0%-12.1% in patients with normal-tension glaucoma.
评估0.03%比马前列素单次治疗3年对眼压（IOP）和视野的影响。
我们每1 - 3个月监测62例正常眼压性青光眼患者的眼压。治疗后每6个月进行一次汉弗莱视野检查，并将所得结果与治疗前结果进行比较。此外，使用趋势分析和事件分析评估视野情况。
比马前列素治疗3年后眼压的平均值±标准差（SD）（13.6±3.1 mmHg）显著低于治疗前（16.8±2.4 mmHg，P<0.0001）。治疗前和治疗3年后汉弗莱视野的平均偏差和模式标准差数值未观察到变化。通过趋势分析，1例患者（3.0%）视野情况恶化；通过事件分析，4例患者（12.1%）视野情况恶化。17例患者（27.4%）因不良反应停药。
0.03%比马前列素单次治疗在至少3年的治疗期间有效降低眼压，但正常眼压性青光眼患者的视野情况恶化了3.0% - 12.1%。
